Some investors asked on the investor interaction platform: does the company have a strategic layout in terms of synthetic biology in the future? What is the progress of the company’s new material project in medical beauty?
Rianlon Corporation(300596) (300596. SZ) said on the investor interaction platform on January 22 that the third life curve of the company is the direction of life science and is in the primary stage of R & D and industrialization. Please pay attention to the announcement of the company.
